Rezivertinib Mesylate Capsules Application Scope

Rezivertinib Mesylate Capsules are indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and have been confirmed to have an EGFR T790M mutation.

rezivertinib mesylate capsules

Rezivertinib Mesylate Capsules Characteristics

Ingredients: Each capsule contains Rezivertinib Mesylate as the active ingredient.
Properties: Rezivertinib is an orally administered, selective, and potent third-generation EGFR TKI that irreversibly inhibits EGFR mutants, including T790M and L858R mutations.
Specification: Available in 30 mg capsules.
Packaging Specification: Typically supplied in blister packs containing a specific number of capsules per pack.
Storage: Store in a cool, dry place away from direct sunlight and moisture.
Expiry Date: Refer to the packaging for the specific expiration date.
Executive Standard: Complies with the standards approved by the National Medical Products Administration (NMPA) of China.
Approval Number: Refer to the packaging or official NMPA documentation for the specific approval number.
Date of Revision: Refer to the latest prescribing information leaflet for the revision date.
Manufacturer: Beta Pharma (Shanghai) Co., Ltd.

Guidelines for Use Rezivertinib Mesylate Capsules

Dosage and Administration:

The recommended dosage is 180 mg taken orally once daily, with or without food.
If adverse reactions occur, the dosage may be reduced to 120 mg once daily based on individual safety and tolerability.

Adverse Reactions:

Common adverse reactions include:

Leukopenia (decreased white blood cell count)
Thrombocytopenia (decreased platelet count)
Anemia
Rash
Elevated aspartate aminotransferase (AST)
Elevated alanine aminotransferase (ALT)
Decreased appetite
Diarrhea

These side effects were observed in clinical studies.

Contraindications

Patients with known hypersensitivity to Rezivertinib or any of its components.

Precautions:

Monitor blood cell counts and liver function tests regularly during treatment.
Use with caution in patients with a history of interstitial lung disease or pneumonitis.

Drug Interactions:

Concomitant use with strong CYP enzyme inducers should be avoided, as they may affect the efficacy of Rezivertinib.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.